secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001178913-25-000700
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Silexion Therapeutics reports positive initial data from SIL204 in orthotopic pancreatic cancer models
--------------------------------------------------------------------------------

- SIL204 reduced primary tumor bioluminescence by ~70% in AsPC-1 (KRAS G12D) and ~80% in BxPC-3 (wild-type) models by day 28.
- In Panc-1 model, SIL204 decreased bioluminescence by 12% vs. baseline while control increased >100% (p<0.05) by day 14.
- Subcutaneous SIL204 significantly reduced metastatic spread to liver, intestine, spleen, and stomach in Panc-1 and BxPC-3 models.
- Data provide initial validation of systemic delivery efficacy for treating both primary tumors and metastases in orthotopic models.
- Company plans to provide updated development strategy leveraging systemic administration approach in coming weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000700/0001178913-25-000700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325000700/zk2532812.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-000700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer